Sei in: Home > Gruppi > "Cancer PharmacoGenomics (CPG)"

"Cancer PharmacoGenomics (CPG)"






The aim of targeted therapy is to block the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth. The possibility to obtain model systems able to reproduce the  genetic alterations present in human cancer could help us to understand the biological characteristics of such mutated cells and to evaluate their response to drugs. We utilize experimental models (e.g. cancer cell lines, isogenic cell lines, patient biopsies)  to investigate the role of mutations in tumor progression and to identify genotype- specific pharmacological responses utilizing a medium-throughput  drug screening method.

Another field of interest is the study of the effect of compounds with potential cytotoxic and/or antiproliferative activity on cancer cell lines with the aim to evidence their mechanisms of action and molecular target, to identify new potential anticancer drugs.

Pharmacogenomics, Cancer, Anticancer drugs, Medium-throughput  drug screening

Aree/Progetti collegati:
Understanding the molecular bases of secondary resistance to EGFR targeted therapies in colorectal cancer 

Ultimo aggiornamento: 14/01/2016 15:25
Campusnet Unito
Non cliccare qui!